Alpine Immune Sciences Q1 EPS $(0.28) Beats $(0.41) Estimate, Sales $7.03M Beat $3.52M Estimate
Portfolio Pulse from Benzinga Newsdesk
Alpine Immune Sciences (NASDAQ:ALPN) reported Q1 earnings with losses of $(0.28) per share, surpassing the $(0.41) estimate, and sales of $7.03M, exceeding the $3.52M estimate. Despite beating estimates, sales decreased by 25.09% from the previous year.
May 09, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alpine Immune Sciences reported better-than-expected Q1 earnings and sales, but experienced a significant year-over-year sales decrease.
Beating earnings and sales estimates typically has a positive impact on stock prices in the short term. However, the significant decrease in sales year-over-year could temper investor enthusiasm, suggesting a mixed but overall positive short-term outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100